Evaluation of physician eye lens doses during permanent seed implant brachytherapy for prostate cancer
Evaluation of physician eye lens doses during permanent seed implant brachytherapy for prostate cancer
复制标题
前列腺癌永久粒子植入近距离放射治疗期间医生眼睛晶状体剂量的评估
DOI：
10.1088/0952-4746/32/3/339
复制
发表时间：
2012
影响因子：
1.5
通讯作者：
J. Asp
中科院分区：
文献类型：
--
作者：
S. Penfold;L. Marcu;J. M. Lawson;J. Asp
用放射性粒子的永久植入治疗低度前列腺癌已经成为当今使用的最常见的近距离放射治疗程序之一。植入手术通常在荧光透视图像引导下进行，以确保粒子在计划位置展开。在这种情况下，执行经会阴植入的医生需要靠近荧光透视单元，并且可能需要关注眼透镜的剂量。1991年，国际辐射防护委员会（ICRP）提出了职业性眼部透镜照射的建议剂量限值为150 mSv/yr-1。随着更多的长期随访数据，这一限值在2011年修订为20 mSv yr-1。考虑到这一修改后的限值，我们研究了前列腺近距离放射治疗粒子植入过程中医生接受的眼睛透镜剂量。通过对年工作量进行近似计算，我们将接收的剂量与年本底剂量联系起来。通过使用热释光剂量计进行临床和体模测量，发现医生眼睛透镜收到的过量剂量（保守估计年工作量）从未超过年本底剂量的100%。
Treatment of low grade prostate cancer with permanent implant of radioactive seeds has become one of the most common brachytherapy procedures in use today. The implant procedure is usually performed with fluoroscopy image guidance to ensure that the seeds are deployed in the planned locations. In this situation the physician performing the transperineal implant is required to be close to the fluoroscopy unit and dose to the eye lens may be of concern. In 1991 the International Commission on Radiological Protection (ICRP) provided a recommended dose limit of 150 mSv yr−1 for occupational exposures to the lens of the eye. With more long term follow-up data, this limit was revised in 2011 to 20 mSv yr−1. With this revised limit in mind, we have investigated the dose to the lens of the eye received by physicians during prostate brachytherapy seed implantation. By making an approximation of annual workload, we have related the dose received to the annual background dose. Through clinical and phantom measurements with thermoluminescent dosimeters, it was found that the excess dose to the physician’s eye lens received for a conservative estimate of annual workload was never greater than 100% of the annual background dose.